In prostate cancer, OGT ablation reduces the expression of angiogenic factors, such as vascular endothelial growth factor, matrix metallopeptidase 2 (MMP2), and MMP9, to block angiogenesis (82). The gene discussed is MMP2; the disease is Familial prostate cancer.